Biotech (XBI) is a publicly traded the market company. As of May 20, 2026, XBI trades at $131.56 with a market cap of $0 and a P/E ratio of 0.00. XBI moved +3.92% today. Year to date, XBI is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces XBI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
XBI flat as biotech M&A tailwinds meet mixed earnings and rate sensitivity: XBI is flat on May 7, 2026, as biotech’s deal-driven bid is being offset by stock-specific earnings and mixed risk appetite in higher-duration areas. The most notable tape driver is continued biotech M&A momentum, highlighted by Angelini Pharma’s announced $4.1B acquisition of Catalyst Pharmaceuticals.
| Metric | Value |
|---|---|
| Price | $131.56 |
| Market Cap | $0 |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.00 |
| 52-Week Low | $0.00 |
| Volume | 10.38M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
XBI analyst coverage data. Average price target: $0.00.